The control of serum LH levels in the GnRH-antagonist protocol is an important factor in ovulation induction therapy, since women with PCOS are usually accompanied by higher basal LH levels and an increased probability of early LH elevation. Here, PLOD1 is linked to polycystic ovary syndrome.